Current Assets
Cash & Equivalents
Gilead Sciences Cash & Equivalents increased by 0.8% to $7.63B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.8%, from $7.93B to $7.63B. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows an upward trend with a 4.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalContext dependent
VolatilityVolatile
First reportedQ4 2012
Last reportedQ1 2026May 7, 2026
How to read this metric
An increase suggests strong liquidity and capacity for investment, while a decrease may indicate heavy capital deployment or cash burn.
Detailed definition
This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term invest...
Peer comparison
Standard across all industries; peers in biotech typically maintain high cash balances to fund long-term clinical trials.
Metric ID:
cash_and_equivalentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.89B | $4.36B | $5.34B | $4.3B | $4.74B | $4.7B | $5.41B | $4.94B | $5.7B | $5.71B | $6.09B | $4.72B | $2.77B | $5.04B | $9.99B | $7.93B | $5.14B | $7.33B | $7.56B | $7.63B |
| QoQ Change | — | -10.9% | +22.4% | -19.5% | +10.3% | -0.8% | +15.2% | -8.8% | +15.6% | +0.0% | +6.7% | -22.5% | -41.2% | +81.7% | +98.4% | -20.7% | -35.1% | +42.5% | +3.2% | +0.8% |
| YoY Change | — | — | — | — | -3.1% | +7.7% | +1.4% | +14.9% | +20.4% | +21.4% | +12.4% | -4.4% | -51.4% | -11.7% | +64.2% | +68.0% | +85.6% | +45.5% | -24.3% | -3.8% |
Range$2.77B – $9.99B
CAGR+9.8%
Avg YoY Growth+15.2%
Median YoY Growth+10.1%
Current Streak3 quarters growth
Cash & Equivalents at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's cash & equivalents?
- Gilead Sciences (GILD) reported cash & equivalents of $7.63B in Q1 2026.
- How has Gilead Sciences's cash & equivalents changed year-over-year?
- Gilead Sciences's cash & equivalents decreased by 3.8% year-over-year, from $7.93B to $7.63B.
- What is the long-term trend for Gilead Sciences's cash & equivalents?
- Over 5 years (2020 to 2025), Gilead Sciences's cash & equivalents has grown at a 4.8% compound annual growth rate (CAGR), from $6B to $7.56B.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid investments the company can access immediately.